Van Hulzen Asset Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.07M | Sell |
17,594
-670
| -4% | -$39.1K | 0.08% | 157 |
|
|
2025
Q4 | $985K | Buy |
18,264
+4,240
| +30% | +$204K | 0.07% | 162 |
|
|
2025
Q3 | $632K | Sell |
14,024
-1,020
| -7% | -$47.6K | 0.05% | 205 |
|
|
2025
Q2 | $696K | Buy |
15,044
+910
| +6% | +$44.7K | 0.06% | 182 |
|
|
2025
Q1 | $862K | Sell |
14,134
-890
| -6% | -$51.9K | 0.08% | 163 |
|
|
2024
Q4 | $850K | Buy |
15,024
+290
| +2% | +$16.2K | 0.06% | 176 |
|
|
2024
Q3 | $762K | Buy |
14,734
+6,254
| +74% | +$293K | 0.06% | 184 |
|
|
2024
Q2 | $352K | Buy |
8,480
+3,087
| +57% | +$138K | 0.02% | 233 |
|
|
2024
Q1 | $292K | Buy |
5,393
+20
| +0.4% | +$1.02K | 0.02% | 268 |
|
|
2023
Q4 | $276K | Hold |
5,373
| – | – | 0.02% | 274 |
|
|
2023
Q3 | $312K | Buy |
5,373
+133
| +3% | +$8.15K | 0.02% | 245 |
|
|
2023
Q2 | $335K | Sell |
5,240
-3,135
| -37% | -$210K | 0.03% | 224 |
|
|
2023
Q1 | $580K | Buy |
8,375
+1,185
| +16% | +$83.6K | 0.05% | 163 |
|
|
2022
Q4 | $517K | Hold |
7,190
| – | – | 0.06% | 172 |
|
|
2022
Q3 | $511K | Sell |
7,190
-56
| -0.8% | -$4.06K | 0.06% | 164 |
|
|
2022
Q2 | $558K | Sell |
7,246
-120
| -2% | -$9.14K | 0.07% | 155 |
|
|
2022
Q1 | $538K | Hold |
7,366
| – | – | 0.06% | 159 |
|
|
2021
Q4 | $459K | Sell |
7,366
-6,640
| -47% | -$390K | 0.05% | 186 |
|
|
2021
Q3 | $829K | Sell |
14,006
-150
| -1% | -$9.88K | 0.12% | 101 |
|
|
2021
Q2 | $946K | Buy |
14,156
+2,690
| +23% | +$175K | 0.14% | 92 |
|
|
2021
Q1 | $724K | Sell |
11,466
-3,654
| -24% | -$227K | 0.12% | 106 |
|
|
2020
Q4 | $938K | Sell |
15,120
-3,114
| -17% | -$191K | 0.14% | 96 |
|
|
2020
Q3 | $1.1M | Sell |
18,234
-251
| -1% | -$15.1K | 0.17% | 94 |
|
|
2020
Q2 | $1.09M | Buy |
18,485
+6,733
| +57% | +$403K | 0.16% | 88 |
|
|
2020
Q1 | $655K | Buy |
11,752
+90
| +0.8% | +$5.5K | 0.14% | 98 |
|
|
2019
Q4 | $749K | Sell |
11,662
-397
| -3% | -$22.7K | 0.15% | 108 |
|
|
2019
Q3 | $612K | Sell |
12,059
-40,478
| -77% | -$1.9M | 0.13% | 112 |
|
|
2019
Q2 | $2.38M | Buy |
52,537
+47,423
| +927% | +$2.21M | 0.52% | 46 |
|
|
2019
Q1 | $244K | Sell |
5,114
-1,015
| -17% | -$50.6K | 0.07% | 198 |
|
|
2018
Q4 | $319K | Hold |
6,129
| – | – | 0.09% | 158 |
|
|
2018
Q3 | $380K | Buy |
6,129
+35
| +0.6% | +$2.08K | 0.1% | 142 |
|
|
2018
Q2 | $337K | Buy |
6,094
+215
| +4% | +$11.6K | 0.1% | 131 |
|
|
2018
Q1 | $372K | Hold |
5,879
| – | – | 0.11% | 125 |
|
|
2017
Q4 | $360K | Hold |
5,879
| – | – | 0.11% | 140 |
|
|
2017
Q3 | $375K | Buy |
5,879
+1,000
| +20% | +$58.4K | 0.13% | 118 |
|
|
2017
Q2 | $272K | Sell |
4,879
-600
| -11% | -$32.6K | 0.11% | 107 |
|
|
2017
Q1 | $298K | Sell |
5,479
-200
| -4% | -$11K | 0.14% | 103 |
|
|
2016
Q4 | $332K | Sell |
5,679
-29,754
| -84% | -$1.63M | 0.15% | 97 |
|
|
2016
Q3 | $1.91M | Buy |
35,433
+5,701
| +19% | +$366K | 1.04% | 35 |
|
|
2016
Q2 | $2.19M | Buy |
29,732
+2,501
| +9% | +$177K | 1.24% | 32 |
|
|
2016
Q1 | $1.74M | Buy |
27,231
+11,343
| +71% | +$715K | 0.99% | 38 |
|
|
2015
Q4 | $1.09M | Buy |
15,888
+4,753
| +43% | +$314K | 0.68% | 47 |
|
|
2015
Q3 | $659K | Sell |
11,135
-102
| -0.9% | -$6.47K | 0.43% | 59 |
|
|
2015
Q2 | $748K | Sell |
11,237
-14,596
| -57% | -$962K | 0.4% | 66 |
|
|
2015
Q1 | $1.67M | Buy |
25,833
+13,347
| +107% | +$836K | 1.02% | 33 |
|
|
2014
Q4 | $737K | Sell |
12,486
-20,864
| -63% | -$1.18M | 0.51% | 52 |
|
|
2014
Q3 | $1.71M | Buy |
+33,350
| New | +$1.67M | 1.73% | 26 |
|
|
2014
Q2 | – | Sell |
-7,879
| Closed | -$409K | – | 67 |
|
|
2014
Q1 | $409K | Sell |
7,879
-100
| -1% | -$5.32K | 0.41% | 61 |
|
|
2013
Q4 | $424K | Buy |
+7,979
| New | +$406K | 0.37% | 67 |
|
Other funds holding BMY
VCM
VPM
Van Hulzen Asset Management's BMY Position: Q1 2026 in Review
Van Hulzen Asset Management reduced its Bristol-Myers Squibb (BMY) stake by 3.7% in Q1 2026, selling an estimated $39.1K and leaving 17,594 shares worth $1.07M. The position accounts for 0.08% of the portfolio, ranked #157.
Van Hulzen Asset Management first reported a position in BMY in Q4 2013 and has held it in 49 quarters since. The position peaked at $2.38M in Q2 2019. 2,521 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Van Hulzen Asset Management held 17,594 shares of Bristol-Myers Squibb worth $1.07M as of Q1 2026.
- Van Hulzen Asset Management sold 670 Bristol-Myers Squibb shares in Q1 2026, an estimated $39.1K.
- Bristol-Myers Squibb made up 0.08% of Van Hulzen Asset Management's portfolio in Q1 2026, its #157 holding.
- Van Hulzen Asset Management first reported a position in Bristol-Myers Squibb in Q4 2013 and has held it in 49 quarters since.
- Van Hulzen Asset Management's Bristol-Myers Squibb position peaked at $2.38M in Q2 2019.
- 2,521 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Van Hulzen Asset Management's 13F filing for Q1 2026, filed 14 May 2026.